Physician profile
Robert D Silver
NPI 1295879567
$806.57
in general payments reported to CMS, 2019-2025
14 companies · $258 in 2025
The $258 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.86 · 2020: $78.64 · 2021: $98.66 · 2022: $40.25 · 2023: $190 · 2024: $109 · 2025: $258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $557.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $142.52 | 2021-2025 | Nucala |
| Aerin Medical INC. | $128.57 | 2019-2025 | |
| Phadia US INC. | $99.48 | 2023-2025 | Immunocap |
| Regeneron Healthcare Solutions, INC. | $85.31 | 2023-2025 | Dupixent |
| Intersect Ent, INC. | $67.25 | 2020 | |
| Preceptis Medical, INC. | $61.48 | 2021 | |
| Medtronic, INC. | $61.22 | 2023-2025 | Propel |
| Optinose US, INC. | $47.45 | 2019-2022 | |
| Hologic Sales and Service, LLC | $29.47 | 2025 | Coolseal Generator |
| Integra Lifesciences Corporation | $21.15 | 2025 | Inspira Air, Acclarent Aera, Relieva Spinplus Nav |
| Astrazeneca Pharmaceuticals Lp | $19.59 | 2025 | Tezspire |
| Phathom Pharmaceuticals, INC. | $17.26 | 2024 | Voquezna |
| Genzyme Corporation | $14.43 | 2023 | |
| Cook Medical LLC | $11.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Silver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.